Michael Mollerus

Davis Polk advised SS&C Technologies Holdings, Inc. on its $1.4 billion public offering of 30,262,250 shares of common stock, including 3,947,250 shares sold pursuant to an underwriters…

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.500% senior notes…

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant…

Davis Polk advised the underwriter in connection with the SEC-registered offering of 4,179,678 shares of common stock of OneMain Holdings, Inc. sold by Springleaf Financial Holdings, LLC on…

Davis Polk is advising Fogo de Chão, Inc. on its $560 million acquisition by Rhône Capital. The transaction is expected to be completed during the second quarter of 2018, subject to…

Davis Polk advised Affimed N.V. on its $26.5 million public offering of 13,225,000 of its common shares. Included in the shares are 1,725,000 shares sold by Affimed pursuant to the…

Davis Polk advised EnVen Energy Corporation in connection with a Rule 144A/Regulation S offering of $325 million aggregate principal amount of its 11.000% senior secured second-lien notes…

Davis Polk is advising Roche on its $1.9 billion acquisition of Flatiron Health, Inc. The transaction, which is expected to close in the first half of 2018, is subject to customary closing…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $800 million acquisition of MPI Research Inc. The transaction, which is expected to close early in…

Davis Polk advised the underwriters in connection with a public offering by IBM Credit LLC of $450 million principal amount of its floating-rate notes due 2021, $800 million principal…